LadRx

LadRx Gross Margin

Gross Margin of LadRx (LADX) as of Oct 23, 2026.

Gross Margin

-

Last updated:

Gross Margin of LadRx is 2026 - . Gross Margin of LadRx was 2025 - . It decreases by % lower compared to the previous year.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

LadRx Stock analysis

What does LadRx do? CytRx Corp. focuses on developing aldoxorubicin, a modified doxorubicin for cancer treatment, currently in Phase III trials for soft tissue sarcoma and multiple other cancer indications. The company generates revenue through clinical trial partnerships and potential future drug sales, targeting pharmaceutical companies and healthcare providers who require novel oncology treatments. CytRx's primary product, aldoxorubicin, is being evaluated in various cancer types including small cell lung cancer and glioblastoma, with additional pre-clinical development for DK049, an anti-cancer drug conjugate using LADR technology. The firm's revenue streams are derived from its clinical development programs and potential licensing agreements with partners in the oncology sector. LadRx is one of the most popular companies on Eulerpool.

Frequently Asked Questions about LadRx stock

On Eulerpool you can find the complete historical development of Gross Margin LadRx since 2006 – with annual values, charts, and detailed analysis.

Gross Margin measures the percentage of revenue remaining after COGS. Higher gross margins indicate more efficient production and stronger pricing power.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Gross Margin's LadRx with sector peers and the industry average to assess whether it is attractive.

To evaluate Gross Margin's, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Gross Margin.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Margins — LadRx

All Key Metrics — LadRx